Navigation Links
Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral,Approach to Treating Inflammatory Diseases

dvance CC-11050 and other compounds from this class of oral TNF alpha inhibitors, as potential novel oral therapies for chronic inflammatory diseases.

"CC-10004 is a unique oral therapy that demonstrates reasonable efficacy and favorable safety profile in a moderate to severe psoriasis setting. The drug is clearly working," said Kim Papp, M.D., Ph.D., Assistant Clinical Professor of Medicine at the University of Western Ontario, Canada and a principle investigator of the Phase II study.

Adverse side effects in patients receiving CC-10004 were mild and well tolerated. Overall, the percentage of patients who reported at least one adverse event in the CC-10004 twice daily arm (54%) was equivalent to that experienced with the placebo arm of the study (60%).

"These positive results validate the potential of our oral class of anti- inflammatory compounds," said Sol J. Barer, Ph.D., Chairman and Chief Executive Officer of Celgene Corporation. "We plan to evaluate multiple opportunities across a broad range of debilitating inflammatory diseases where there are limited effective oral treatment options for these devastating conditions."

About the Phase II Study

This Phase II study was a multicenter, randomized, double blind, placebo- controlled, parallel-group, dose comparison efficacy study in 260 patients with moderate-to-severe plaque-type psoriasis who were candidates for systemic therapy. Patients who participated in this study were required to have a minimum of a 6-month history of moderate-to-severe plaque-type psoriasis prior to enrollment.

About Chronic Inflammatory Diseases

Chronic inflammatory diseases are caused by persistent stimulus to tissues in the body over a prolonged period of time resulting in inflammation. This class of diseases includes immune-mediated conditions, such as rheumatoid arthritis and psoriasis, where a person's immune system attacks their own body tissues trying to heal and repair them, but ul
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:4/28/2015)... N.J. , April 28, 2015 As ... Stryker Orthopaedics, is kicking off tournament week by heading ... second consecutive year appearing at the tournament, Stryker continues ... about the importance of joint health and mobility. As ... , Stryker is bringing new features to enhance ...
(Date:4/28/2015)... April 28, 2015   HX360 today ... of the inaugural HX360 Innovation Challenge ... improved patient experience in hospital and health system ... original field of eighty-three entries, with the four ... panel during the HX360 Innovation Challenge program at ...
(Date:4/28/2015)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... I am very excited to announce that we ... clinical trial for oral insulin (ORMD-0801) and the treatment of ... in the coming weeks. This clinical trial will be our largest ... milestone for the company, literally putting us in a different ...
Breaking Medicine Technology:The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 2The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 3The Stryker Mobility Zone Heads to Insperity Invitational for Second Consecutive Year 4Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 2Ginger.io And WiserCare Named Winners Of The HX360 Innovation Challenge 3Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 2Oramed Pharmaceuticals Inc. Issues Phase IIb Study Update Letter 3
... Aug. 2 Cytokine PharmaSciences,Inc. (CPSI) today ... inhibitors showed oral efficacy in animal models. ... it is advancing one of these compounds,into ... or MIF, is linked to many,conditions, including ...
... ARBOR, Mich., Aug. 3 Far more of today,s,heart attack ... clogged heart arteries than even a,decade ago, a new study ... from this urgent treatment,-- which is known to save lives ... it at all, the study shows. And the chance ...
Cached Medicine Technology:Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors 2Many Heart Attack Patients Don't Get Best Emergency Treatment 2Many Heart Attack Patients Don't Get Best Emergency Treatment 3Many Heart Attack Patients Don't Get Best Emergency Treatment 4
(Date:4/28/2015)... 28, 2015 OsteoRemedies®, LLC, Memphis, ... two-stage revision of infected hip and knee arthroplasty. ... as a pre-formed, pre-loaded spacer with Gentamicin Antibiotics, ... joint space. Combined with a consistent process ... spacer is approved for temporary use for up ...
(Date:4/28/2015)... CA (PRWEB) April 28, 2015 Once considered ... Grow Lights have taken the industry by storm with perfectly ... to use unit. , More than half of ... KIND LED , proving the stigma is gone and ... The overwhelming positive response from customers and their first hand ...
(Date:4/28/2015)... 2015 Jovium®, a brand focused on ... better emotional balance, has begun to increase its market ... scale to enhance their mood and relieve some of ... Jovium® System aims to help patients overcome some of ... through all-natural products that do not cause or carry ...
(Date:4/28/2015)... NV (PRWEB) April 28, 2015 According ... Center for Ethics (June 27, 2014), prescription drugs ... world. Medical Science is becoming increasingly aware of the ... the market, such as chemotherapy drugs to treat cancer, ... that are quickly evolving to become increasingly resistant to ...
(Date:4/28/2015)... Foot and Ankle Specialists of ... Palmer ( Annapolis and Clarksville Divisions ) was ... the Maryland Podiatric Medical Association meeting on April 15, ... in 1992 with a Bachelor of Arts in Life ... intercollegiate soccer, track and cross-country. He then attended the ...
Breaking Medicine News(10 mins):Health News:SuperCloset Reports Surge in KIND LED Grow Light Sales, Saving Indoor Growing Enthusiasts up to 40% on their Power Usage. 2Health News:Jovium® Products Help Customers to Achieve Emotional Balance 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 2Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 3Health News:Trivedi Science™ Announces the Beginning of Their Science Research to Create Highly Effective Pharmaceutical Drugs with Minimal Side Effects 4Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Podiatrist Receives Maryland Podiatric Medical Association Outstanding Service Award 2
... , , CUPERTINO, Calif., July ... that Matthew Hogan, Chief Financial Officer, will be presenting at the ... August 5 at 4:00 pm Eastern Time. The conference is ... A webcast of the presentation will be accessible at: ...
... , WASHINGTON, July 28 The ... House of Representatives, goal of expanding health coverage to a ... the Society urges the House to make significant revisions to ... care its first priority and protect patient access to specialists. ...
... FRANKLIN LAKES, N.J., July 28 The Board of Directors ... a quarterly dividend of 33 cents per common share, payable on September ... annual dividend rate is $1.32 per share. , , ... technology company that develops, manufactures and sells medical devices, instrument systems and ...
... , MORRISTOWN, N.J., July 28 Watson Pharmaceuticals, ... and specialty branded pharmaceuticals, today announced a license agreement with ... generic version of Ferrlecit (sodium ferric gluconate complex in sucrose ... anemia in hemodialysis patients receiving supplemental epoetin therapy. , ...
... , , Hoag Hospital recognized ... providing optimal level care to breastfeeding mothers and infants , ... Memorial Hospital Presbyterian announced today its designation as a certified Baby-Friendly ... World Health Organization (WHO) and the United Nations Children,s Fund (UNICEF). ...
... PHILADELPHIA Cancer researchers are turning to mathematical models ... paper in Cancer Research , a journal of ... technique may answer questions about Herceptin resistance. ... Oncology Program at the University of Michigan Comprehensive Cancer ...
Cached Medicine News:Health News:DURECT to Present at the BMO Capital Markets Healthcare Conference 2Health News:SCAI Opposes U.S. House of Representatives Health Reform Bill in Current Form 2Health News:SCAI Opposes U.S. House of Representatives Health Reform Bill in Current Form 3Health News:Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R) 2Health News:Hoag Hospital Certified as Baby-Friendly Facility 2Health News:Hoag Hospital Certified as Baby-Friendly Facility 3Health News:Mathematical modeling predicts response to Herceptin 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: